Oxford Company To Develop Synthetic Tissue For Organ Repair

An Oxford Uni spin out company plans to develop a new technique that can create human tissue through 3D printers.


With patient safety paramount, the Academy reviewed the current rotation system for trainee doctors and recommend changes where appropriate under the approval of the four UK Health Departments.  The proposals, produced by the Academy's Staggered Trainee Changeover Working Group, which comprised medical Royal Colleges and medical education specialists, were considered by the four UK health department's Medical Education Scrutiny Group's Reference Panel in January of this year, which said that the paper's recommendations should be considered in more detail within the initial scoping work that is underway to take forward the Shape of Training Review.

It's made with thousands of tiny water droplets, coated in a thin film mimicking a living cell's external membrane.

OxSyBio say in the long term their aim is to be able to print synthetic tissues for organ repair or replacement, wound healing and drug delivery.

Isis Innovation, the University's research commercialisation company, announced that OxSyBio has raised £1 million from IP Group plc, the developer of intellectual property based businesses, subject to the achievement of milestones.

The new company will refine and advance the 3D droplet printing technology devised by Professor Hagan Bayley's group at the University's Department of Chemistry. 

Professor Hagan Bayley said: "We have been able to print networks of droplets through which electrical impulses can be transmitted in a manner similar to the way cells in the nervous system communicate: the signal moves rapidly and in a specific direction.

"We also aim to integrate printed tissue-like materials with living tissues, and to print materials that themselves contain living cells.

 "Our long-term goal is to develop a synthetic-tissue printer that a surgeon can use in the operating theatre. In ten years' time, the use of pieces of synthetic tissue will be commonplace. The fabrication of complex synthetic organs is a more distant prospect.

"I am delighted to be working with Isis and IP Group to accelerate the development of our new company, OxSyBio. Our goal is to establish ourselves at the frontline of regenerative medicine."


Source: JackFM2



qr code

About The Operating Theatre Journal

The Operating Theatre Journal, OTJ, is published monthly and distributed to every hospital operating theatre department in the UK. The distribution includes both the National Health Service and the Private Sector.

More »
Follow & Share

Follow The Operating Theatre Journal on Facebook Follow The Operating Theatre Journal on Twitter Follow The Operating Theatre Journal on LinkedIn Follow The Operating Theatre Journal RSS Feed

Help & Support

Problems with, or comments about, this website may be emailed to:

Get in touch

Telephone: +44 (0)2921 680068
Skype: Lawrand Ltd
Email: admin@lawrand.com